The funding will go toward expanding the firm's product line and increasing access to its testing services. MyLab Box has raised $2.1 million in total.
The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
VolitionRx has reached a definitive agreement with an investor for the placement of 5 million shares of the firm's stock at $1.80 per share.
The San Diego-based company is ramping up efforts to market its handheld molecular influenza test in anticipation of the upcoming flu season.
The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.
The company said it plans to use the financing to increase adoption of its MammaPrint BluePrint next-generation sequencing-based test kit for breast cancer.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.
The firm said it will use the funds to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer.